Earnings Call · Q2 FY2022·2022-08-08

Q2 22EPS 0.00%·Rev n/aQ1 22EPS +7.35%·Rev n/aQ4 21EPS +100.00%*·Rev n/aQ3 21EPS +29.82%·Rev n/a⚠ consensus missing

Syndax Pharmaceuticals Inc SNDX

Sharon Klahre — Head of Investor Relations

Michael Metzger — Chief Executive Officer

Briggs Morrison — Chief Medical Officer

Keith Goldan — Chief Financial Officer

−1.2%1d on move date−0.8% vs SPY3d−2.6%5d+1.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SNDX calls or request research access.

More SNDX calls Browse calls Request research access